Viking Therapeutics, Inc. (0VQA)
London Exchange · UK · prices in USD · close of 23 Oct 2026
Key indicators
| Last close | USD 24.50 |
|---|---|
| 52-week range | 24.46 – 45.90 |
| Return, 1 month / 3 months | −40.8% / −31.9% |
| Return, 1 year / 3 years | – / – |
| Trend | Below its 200-day average |
| RSI (14) | 35 |
| Volatility (1 year) | 65.2% |
| Worst drawdown (1 year) | -40.8% |
| Average daily value traded | 0.82M USD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Viking Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, California, that develops treatments for metabolic and endocrine disorders. Its work centres on drug candidates for obesity and related conditions, including an injectable and an oral medicine that act on gut hormone receptors, and an oral compound aimed at a liver disease linked to fat accumulation. The company carries out research and clinical testing rather than marketing approved products, and its activities serve patients and physicians in the metabolic disease field.
The shares are listed on the London Exchange in UK under the code 0VQA, and the price on this page is in US dollars (USD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Viking Therapeutics, Inc. (0VQA) trades on the London Exchange in UK. It last closed at USD 24.50 on 23 October 2026.
Its price-based Market X-Ray is 24 out of 100 (a weak price profile), ranking 3,320 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 21 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -24.8% | ||
| From 52-week high | -40.8% | ||
| Momentum | 10 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -31.9% | ||
| 6-month return | -26.5% | ||
| 12-month return, skipping the last month | – | ||
| Stability (higher is calmer) | 23 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 65.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -40.8% | ||
| Liquidity | 51 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.82M USD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −3.0% |
|---|---|
| 1 month | −40.8% |
| 3 months | −31.9% |
| 6 months | −26.5% |
| 1 year | – |
| 3 years | – |
| 5 years | – |
Signals
| 50-day / 200-day average | 31.29 / 32.57 |
|---|---|
| Golden / death cross (60 days) | Death, 13 days ago |
| New 52-week high | No |
| Bullish RSI divergence | Yes |
| Average daily range (ATR) | 1.92 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.